Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.63 |
| ▸ | BRD4 | O60885 | 5/20 | 0.63 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417761 | 1.00 | CREBBP (0.63) | CREBBPBRD4EP300NOS2ALOX5 | |
| SCHEMBL1502374 | 0.82 | ALDH1A1 (0.51) | CREBBPBRD4 | |
| SCHEMBL11771368 | 0.78 | ALDH1A1 (0.40) | CREBBPBRD4TNKS2S100A4 | |
| SCHEMBL4020604 | 0.78 | CYP1A2 (0.56) | CREBBPBRD4TSHR | |
| SCHEMBL4907068 | 0.77 | CREBBP (1.00) | CREBBPBRD4EP300 | |
| SCHEMBL17680224 | 0.77 | CREBBP (1.00) | CREBBPBRD4EP300 | |
| SCHEMBL4018688 | 0.77 | HSD17B10 (0.48) | CREBBPBRD4TNKS2 | |
| SCHEMBL13960699 | 0.77 | HSD17B10 (0.48) | CREBBPBRD4TNKS2 | |
| SCHEMBL4018690 | 0.77 | HSD17B10 (0.48) | CREBBPBRD4TNKS2 | |
| SCHEMBL22955423 | 0.76 | CREBBP (0.59) | CREBBPBRD4MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1283055-A1 | SOLUBLE BETA AMYLOID PRECURSOR PROTEIN SECRETION PROMOTERS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | APP, BDNF, BACE1 | CREBBP 142/4885BRD4 4025/4885EP300 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.